The influence of neurotrophic factors treatment on stroke volume

Romanian Journal of Neurology/ Revista Romana de Neurologie

Volumn 12, Issue 3, 2013, Pages 124-129

  Stan, Adina Dora ^a   Badisor, Alexandru ^b   Birle, Codruta ^a   Blesneag, Alina Vasilica ^a   Opincariu, Iulian ^a   Iancu, Mihaela ^a   Racasan, Dana ^b   Muresanu, Dafin Fior ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Anaesthesia and Intensive Care Compartment Orthopedic Clinic   (Romania)

Author keywords

Cerebrolysin; MRI stroke volume; Neuroprotection

Indexed keywords

CEREBROLYSIN; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL;

EID: 84884394259     PISSN: 18438148     EISSN: 20696094     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lloyd-Jones D., Adams R., Carnethon M. et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:e21-e181
2. Source: Eurostat (online data code: hlth_cd_asdr) 7/2012-Statistics in focus http://epp.eurostat.ec.europa.eu/portal/page/ portal/health/public_health/data_public_health/database European Union, ISSN 1977-0316 Catalogue number:KS-SF-12-007-EN-N
3. The European Stroke Organisation (ESO) Executive Committee and the ESO writing Committee. Guidelines for the management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
4. Donnan G.A., Davis S.M., Parsons M.W., Ma H. et al. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat. Rev. Neurol 2011; 7:400-409.
5. Goldstein L.B. Acute ischemic stroke treatment in 2007. Circulation 2007; 116:1504-14.
6. Muresanu D.F., Buzoianu A., Florian S.I., von Wild T. Towards a roadmap in brain protection and recovery. J Cell Mol Med 2012; 16:2861-71.
7. O'Collins V.E., Macleod M.R., Donnan G.A. et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59:467-77.
8. Sahota P., Savitz S.I. Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 2011; 8:434-51.
9. Lang W., Stadler C.H., Poljakovic Z., Fleet D. Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke 2013; 8:95-104.
10. Masliah E., Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today 2012; 4(Suppl A):3-24.
11. Saver J.L. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis 2008; 5:167-77.
12. Prajapati K.D., Sharma S.S., Roy N. Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci 2011; 22:355-63.
13. Schäbitz W.R. et al. AXIS. A trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 2010; 41:2545-51.
14. Stankowski J.N., Gupta R. Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation?. Antioxid Redox Signal 2011; 14:1841-51
15. Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not the way we tried it before. Stroke 2010; 41(10 Suppl):S87-90.
16. C. Weimar I.R., Konig K., Kraywinkel et al. Age and National Institutes of Health Stroke Scale Score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: Development and external validation of prognostic models. Stroke 2004; 35:158-62.
17. Adams Jr H.P., Davis P.H., Leira E.C. et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53:126-31.
18. Tei H., Uchiyama S., Usui T., Ohara K. Diffusion-weighted ASPECTS as an independent marker for predicting functional outcome. J Neurol 2011; 258:559-65.
19. Thome J., Doppler E. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today 2012;48 Suppl A:63-9.
20. Wronski R, Kronawetter S, Hutter-Paier B et al. A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons. J Neural Transm 2000;59(Suppl):263-72.
21. Zhang L, Chopp M, Meier DH et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke 2013;44:1965-72.
22. Darsalia V, Heldmann U, Lindvall O, Kokaia Z. Stroke-induced neurogenesis in aged brain. Stroke 2005;36:1790-5.
23. Gaudinski MR, Henning EC, Miracle A et al. Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke 2008;39:2765-8
24. Lansberg MG, O'Brien MW, Tong DC et al. Evolution of cerebral infarct volume assessed by diffusion-weighted magnetic resonance imaging. Arch Neurol 2001;58: 613-7.
25. Heiss WD, Huber M, Fink GR et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Meta.1992;12:193-203.
26. Saver JL. Time is brain-quantified. Stroke 2006; 37: 263-6.
27. Thored P, Arvidsson A, Cacci E et al. Persistent production of neurons from adult brain stem cells during recovery after stroke. Stem Cells 2006;24:739-47.
28. Thored P, Heldmann U, Gomes-Leal W et al. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 2009;57:835-49.
29. Abe K. Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 2000;20:1393-408.
30. Shamalov NA. Stakhovskaia LV, Burenchev DV et al. The effect of Cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2010;110:34-7.
31. Skvortsova VI, Stakhovskaia LV, Gubskiǐ LV et al. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2004;(Suppl 11):51-5.